Dose conversion from recombinant human erythropoietin to darbepoetin alfa: Recommendations from clinical studies

Pharmacotherapy

Volumn 22, Issue 9 II, 2002, Pages

  Scott, Shane D ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SIALIC ACID; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DOSE CALCULATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; HUMAN; NONHUMAN; REVIEW; SOLID TUMOR; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG LABELING; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NEOPLASM; PHARMACOKINETICS;

ANEMIA; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG LABELING; EPOETIN ALFA; ERYTHROPOIETIN; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; NEOPLASMS; THERAPEUTIC EQUIVALENCY;

EID: 0036367982     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.14.160s.33398     Document Type: Review

References (14)

1. Development and characterization of novel erythropoiesis stimulating protein (NESP)
2. Optimizing the management of anemia in patients with cancer: A randomized, active-controlled study investigating the dosing of darbepoetin alfa
3. Randomized, double-blind, placebo-controlled, dose-finding study of darbepoetin alfa administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumors
4. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients
5. Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin (Hgb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (rHuEPO) in ESRD patients
6. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (Hgb) in ESRD patients when administered once weekly or once every other week
7. Novel erythropoiesis stimulating protein (NESP) safely maintains hemoglobin concentration levels in hemodialysis patients as effectively as r-HuEPO when administered once-weekly
8. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients
9. Reduced dosing frequency with darbepoetin alfa compared with rHuEPO for treatment of anemia in patients with chronic kidney disease receiving dialysis
10. Darbepoetin alfa administered every 1 or 2 weeks (with no loss of dose efficiency) alleviates anemia in patients with solid tumors
11. Darbepoetin alfa given every one or two weeks alleviates anaemia associated with cancer chemotherapy
12. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly
13. Novel erythropoiesis-stimulating protein, an erythropoietin analogue with an extended half-life and less frequent dosing